Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle

Sachiko Ohshima, Jin Hong Shin, Katsutoshi Yuasa, Akiyo Nishiyama, Jun-Ichi Kira, Takashi Okada, Shin'ichi Takeda

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Recombinant adeno-associated virus (rAAV)-mediated gene transfer is an attractive approach to the treatment of Duchenne muscular dystrophy (DMD). We investigated the muscle transduction profiles and immune responses associated with the administration of rAAV2 and rAAV8 in normal and canine X-linked muscular dystrophy in Japan (CXMDJ) dogs. rAAV2 or rAAV8 encoding the lacZ gene was injected into the skeletal muscles of normal dogs. Two weeks after the injection, we detected a larger number of β-galactosidase-positive fibers in rAAV8-transduced canine skeletal muscle than in rAAV2-transduced muscle. Although immunohistochemical analysis using anti-CD4 and anti-CD8 antibodies revealed less T-cell response to rAAV8 than to rAAV2, β-galactosidase expression in rAAV8-injected muscle lasted for <4 weeks with intramuscular transduction. Canine bone marrow-derived dendritic cells (DCs) were activated by both rAAV2 and rAAV8, implying that innate immunity might be involved in both cases. Intravenous administration of rAAV8-lacZ into the hind limb in normal dogs and rAAV8-microdystrophin into the hind limb in CXMDJ dogs resulted in improved transgene expression in the skeletal muscles lasting over a period of 8 weeks, but with a declining trend. The limb perfusion transduction protocol with adequate immune modulation would further enhance the rAAV8-mediated transduction strategy and lead to therapeutic benefits in DMD gene therapy.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalMolecular Therapy
Volume17
Issue number1
DOIs
Publication statusPublished - Jan 1 2009

Fingerprint

Canidae
Skeletal Muscle
Galactosidases
Dogs
Extremities
Duchenne Muscular Dystrophy
Muscular Dystrophies
Muscles
Japan
Dependovirus
Lac Operon
Transgenes
Innate Immunity
Intravenous Administration
Genetic Therapy
Dendritic Cells
Anti-Idiotypic Antibodies
Perfusion
Bone Marrow
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. / Ohshima, Sachiko; Shin, Jin Hong; Yuasa, Katsutoshi; Nishiyama, Akiyo; Kira, Jun-Ichi; Okada, Takashi; Takeda, Shin'ichi.

In: Molecular Therapy, Vol. 17, No. 1, 01.01.2009, p. 73-80.

Research output: Contribution to journalArticle

Ohshima, Sachiko ; Shin, Jin Hong ; Yuasa, Katsutoshi ; Nishiyama, Akiyo ; Kira, Jun-Ichi ; Okada, Takashi ; Takeda, Shin'ichi. / Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. In: Molecular Therapy. 2009 ; Vol. 17, No. 1. pp. 73-80.
@article{a576aa7aa7f64b7ba532022193dde390,
title = "Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle",
abstract = "Recombinant adeno-associated virus (rAAV)-mediated gene transfer is an attractive approach to the treatment of Duchenne muscular dystrophy (DMD). We investigated the muscle transduction profiles and immune responses associated with the administration of rAAV2 and rAAV8 in normal and canine X-linked muscular dystrophy in Japan (CXMDJ) dogs. rAAV2 or rAAV8 encoding the lacZ gene was injected into the skeletal muscles of normal dogs. Two weeks after the injection, we detected a larger number of β-galactosidase-positive fibers in rAAV8-transduced canine skeletal muscle than in rAAV2-transduced muscle. Although immunohistochemical analysis using anti-CD4 and anti-CD8 antibodies revealed less T-cell response to rAAV8 than to rAAV2, β-galactosidase expression in rAAV8-injected muscle lasted for <4 weeks with intramuscular transduction. Canine bone marrow-derived dendritic cells (DCs) were activated by both rAAV2 and rAAV8, implying that innate immunity might be involved in both cases. Intravenous administration of rAAV8-lacZ into the hind limb in normal dogs and rAAV8-microdystrophin into the hind limb in CXMDJ dogs resulted in improved transgene expression in the skeletal muscles lasting over a period of 8 weeks, but with a declining trend. The limb perfusion transduction protocol with adequate immune modulation would further enhance the rAAV8-mediated transduction strategy and lead to therapeutic benefits in DMD gene therapy.",
author = "Sachiko Ohshima and Shin, {Jin Hong} and Katsutoshi Yuasa and Akiyo Nishiyama and Jun-Ichi Kira and Takashi Okada and Shin'ichi Takeda",
year = "2009",
month = "1",
day = "1",
doi = "10.1038/mt.2008.225",
language = "English",
volume = "17",
pages = "73--80",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle

AU - Ohshima, Sachiko

AU - Shin, Jin Hong

AU - Yuasa, Katsutoshi

AU - Nishiyama, Akiyo

AU - Kira, Jun-Ichi

AU - Okada, Takashi

AU - Takeda, Shin'ichi

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Recombinant adeno-associated virus (rAAV)-mediated gene transfer is an attractive approach to the treatment of Duchenne muscular dystrophy (DMD). We investigated the muscle transduction profiles and immune responses associated with the administration of rAAV2 and rAAV8 in normal and canine X-linked muscular dystrophy in Japan (CXMDJ) dogs. rAAV2 or rAAV8 encoding the lacZ gene was injected into the skeletal muscles of normal dogs. Two weeks after the injection, we detected a larger number of β-galactosidase-positive fibers in rAAV8-transduced canine skeletal muscle than in rAAV2-transduced muscle. Although immunohistochemical analysis using anti-CD4 and anti-CD8 antibodies revealed less T-cell response to rAAV8 than to rAAV2, β-galactosidase expression in rAAV8-injected muscle lasted for <4 weeks with intramuscular transduction. Canine bone marrow-derived dendritic cells (DCs) were activated by both rAAV2 and rAAV8, implying that innate immunity might be involved in both cases. Intravenous administration of rAAV8-lacZ into the hind limb in normal dogs and rAAV8-microdystrophin into the hind limb in CXMDJ dogs resulted in improved transgene expression in the skeletal muscles lasting over a period of 8 weeks, but with a declining trend. The limb perfusion transduction protocol with adequate immune modulation would further enhance the rAAV8-mediated transduction strategy and lead to therapeutic benefits in DMD gene therapy.

AB - Recombinant adeno-associated virus (rAAV)-mediated gene transfer is an attractive approach to the treatment of Duchenne muscular dystrophy (DMD). We investigated the muscle transduction profiles and immune responses associated with the administration of rAAV2 and rAAV8 in normal and canine X-linked muscular dystrophy in Japan (CXMDJ) dogs. rAAV2 or rAAV8 encoding the lacZ gene was injected into the skeletal muscles of normal dogs. Two weeks after the injection, we detected a larger number of β-galactosidase-positive fibers in rAAV8-transduced canine skeletal muscle than in rAAV2-transduced muscle. Although immunohistochemical analysis using anti-CD4 and anti-CD8 antibodies revealed less T-cell response to rAAV8 than to rAAV2, β-galactosidase expression in rAAV8-injected muscle lasted for <4 weeks with intramuscular transduction. Canine bone marrow-derived dendritic cells (DCs) were activated by both rAAV2 and rAAV8, implying that innate immunity might be involved in both cases. Intravenous administration of rAAV8-lacZ into the hind limb in normal dogs and rAAV8-microdystrophin into the hind limb in CXMDJ dogs resulted in improved transgene expression in the skeletal muscles lasting over a period of 8 weeks, but with a declining trend. The limb perfusion transduction protocol with adequate immune modulation would further enhance the rAAV8-mediated transduction strategy and lead to therapeutic benefits in DMD gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=58149259952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149259952&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.225

DO - 10.1038/mt.2008.225

M3 - Article

C2 - 18941441

AN - SCOPUS:58149259952

VL - 17

SP - 73

EP - 80

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -